Pharvaris Unveils Promising Data on Deucrictibant for Bradykinin-Mediated Angioedema at EAACI Congress 2025

Reuters

06/16

Pharvaris Unveils Promising Data on Deucrictibant for Bradykinin-Mediated Angioedema at EAACI Congress 2025

Pharvaris NV (Nasdaq: PHVS), a late-stage biopharmaceutical company, has announced the presentation of data at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, highlighting the potential of deucrictibant in preventing and treating bradykinin-mediated angioedema attacks. The data demonstrated deucrictibant's potential to address unmet needs for individuals with bradykinin-mediated diseases, such as hereditary angioedema $(HAE)$ and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). The findings from the CHAPTER-1 and RAPIDe-2 studies indicated sustained attack reduction and improvement in quality of life. Additionally, the upcoming RAPIDe-3 phase 3 on-demand study will explore "end-of-progression" as a new pre-specified endpoint. Currently, there are no approved therapies for AAE-C1INH attacks, and Pharvaris' research aims to fill this gap. The posters with detailed findings are available on the Pharvaris website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9469000-en) on June 16, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2543799576"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543799576\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2543799576?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-16 18:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543799576","market":"fut","top_or_hot":-1,"title":"Pharvaris Unveils Promising Data on Deucrictibant for Bradykinin-Mediated Angioedema at EAACI Congress 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pharvaris Unveils Promising Data on Deucrictibant for Bradykinin-Mediated Angioedema at EAACI Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pharvaris NV (Nasdaq: PHVS), a late-stage biopharmaceutical company, has announced the presentation of data at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, highlighting the potential of deucrictibant in preventing and treating bradykinin-mediated angioedema attacks. The data demonstrated deucrictibant's potential to address unmet needs for individuals with bradykinin-mediated diseases, such as hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). The findings from the CHAPTER-1 and RAPIDe-2 studies indicated sustained attack reduction and improvement in quality of life. Additionally, the upcoming RAPIDe-3 phase 3 on-demand study will explore \"end-of-progression\" as a new pre-specified endpoint. Currently, there are no approved therapies for AAE-C1INH attacks, and Pharvaris' research aims to fill this gap. The posters with detailed findings are available on the Pharvaris website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9469000-en) on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharvaris Unveils Promising Data on Deucrictibant for Bradykinin-Mediated Angioedema at EAACI Congress 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharvaris Unveils Promising Data on Deucrictibant for Bradykinin-Mediated Angioedema at EAACI Congress 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-16 18:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pharvaris Unveils Promising Data on Deucrictibant for Bradykinin-Mediated Angioedema at EAACI Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pharvaris NV (Nasdaq: PHVS), a late-stage biopharmaceutical company, has announced the presentation of data at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, highlighting the potential of deucrictibant in preventing and treating bradykinin-mediated angioedema attacks. The data demonstrated deucrictibant's potential to address unmet needs for individuals with bradykinin-mediated diseases, such as hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). The findings from the CHAPTER-1 and RAPIDe-2 studies indicated sustained attack reduction and improvement in quality of life. Additionally, the upcoming RAPIDe-3 phase 3 on-demand study will explore \"end-of-progression\" as a new pre-specified endpoint. Currently, there are no approved therapies for AAE-C1INH attacks, and Pharvaris' research aims to fill this gap. The posters with detailed findings are available on the Pharvaris website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9469000-en) on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和数据","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDL37n2Yk:1","article_id":"2543799576","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543799576","pubTimestamp":1750071021,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pharvaris NV , a late-stage biopharmaceutical company, has announced the presentation of data at the European Academy of Allergy and Clinical Immunology  Congress 2025, highlighting the potential of deucrictibant in preventing and treating bradykinin-mediated angioedema attacks. The data demonstrated deucrictibant's potential to address unmet needs for individuals with bradykinin-mediated diseases, such as hereditary angioedema  and acquired angioedema due to C1 inhibitor deficiency . The findings from the CHAPTER-1 and RAPIDe-2 studies indicated sustained attack reduction and improvement in quality of life. Additionally, the upcoming RAPIDe-3 phase 3 on-demand study will explore \"end-of-progression\" as a new pre-specified endpoint. Currently, there are no approved therapies for AAE-C1INH attacks, and Pharvaris' research aims to fill this gap. The posters with detailed findings are available on the Pharvaris website.Disclaimer: This news brief was created by Public Technologies  using ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","PHVS":"Pharvaris N.V.","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4007":"制药","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"Pharvaris在2025年EAACI大会上公布了Deucrictibant治疗缓激肽介导的血管性水肿的有希望的数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"PHVS":0.9},"content_text":"Pharvaris Unveils Promising Data on Deucrictibant for Bradykinin-Mediated Angioedema at EAACI Congress 2025\n    \n\n        Pharvaris NV (Nasdaq: PHVS), a late-stage biopharmaceutical company, has announced the presentation of data at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, highlighting the potential of deucrictibant in preventing and treating bradykinin-mediated angioedema attacks. The data demonstrated deucrictibant's potential to address unmet needs for individuals with bradykinin-mediated diseases, such as hereditary angioedema $(HAE)$ and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). The findings from the CHAPTER-1 and RAPIDe-2 studies indicated sustained attack reduction and improvement in quality of life. Additionally, the upcoming RAPIDe-3 phase 3 on-demand study will explore \"end-of-progression\" as a new pre-specified endpoint. Currently, there are no approved therapies for AAE-C1INH attacks, and Pharvaris' research aims to fill this gap. The posters with detailed findings are available on the Pharvaris website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9469000-en) on June 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}